Arlington Research Center, Inc.

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)	Plaque Psoriasis	Active, not recruiting	Phase 3	2026-09-28	NCT06220604
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis	Plaque Psoriasis	Active, not recruiting	Phase 3	2026-09-28	NCT06095115
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis	Plaque Psoriasis	Active, not recruiting	Phase 3	2026-09-25	NCT06934226
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)	Plaque Psoriasis	Active, not recruiting	Phase 3	2026-09-25	NCT06095102
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.	Moderate to Severe Genital Psoriasis	Active, not recruiting	Phase 3	2026-09-01	NCT06611163
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa	Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder	Recruiting	Phase 2	2026-03-06	NCT07244263

Clinical trials